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System for MR Image–guided
Prostate Interventions:
Canine Study1
The purpose of this study was to
demonstrate the use of a transrectal
system that enables precise magnetic
resonance (MR) image guidance and
monitoring of prostate interventions.
The system used a closed-bore 1.5-T
MR imaging unit and enables one to
take advantage of the higher signal-
to-noise ratio achieved with tradi-
tional magnet designs, which is cru-
cial for accurate targeting and
monitoring of prostate interventions.
In the first of the four canine studies,
reliable needle placement, with all
needles placed within 2 mm of the
desired target site, was achieved. In
two other studies, MR imaging was
used to monitor distribution of in-
jected contrast agent solution (gado-
pentetate dimeglumine mixed with
trypan blue dye) in and around the
prostate, thereby confirming that so-
lution had been delivered to the de-
sired tissue and also detecting faulty
injections. In the final study, accurate
placement and MR imaging of brachy-
therapy seeds in the prostate were
demonstrated. The described system
provides a flexible platform for a va-
riety of minimally invasive MR im-
age–guided therapeutic and diag-
nostic prostate interventions.
© RSNA, 2003
Prostate carcinoma is the most com-
monly diagnosed life-threatening cancer
in men in the United States. In 2002, the
estimated incidence of this disease in
male patients in the United States was
189,000 (1). As the incidence of prostate
cancer is known to increase with age, this
cancer will become more common as the
U.S. population ages (2). Moreover, due
to the widespread acceptance of prostate-
specific antigen screening, routine rectal
examination, and transrectal ultrasono-
graphic (US) image–guided prostate bi-
opsy, there has been a great increase in
the early detection of prostate cancer (3).
Despite this early detection, the appro-
priate clinical management of prostate
cancer is a very controversial subject.
There is serious debate regarding the clin-
ical relevance of low-grade prostate can-
cer. In some cases, prostate cancers grow
very slowly and never become clinically
important, whereas in other cases, these
cancers are very aggressive and danger-
ous. Because foci of prostate cancer have
been incidentally discovered at autopsy
in more than 30% of men older than 50
years, it is clear that aggressive treatment
is not always appropriate for this malig-
nancy (4,5). Nevertheless, reports (6–8)
have shown that overly conservative
management (ie, “watchful waiting”) can
result in poor patient outcomes. Clinical
decision making is further complicated
by the fact that most prostate cancers are
assessed at diagnosis as “intermediate
stage” and therefore carry an uncertain
prognosis (9).
Currently, the two most accepted
methods for treatment of localized pros-
tate cancer are radical prostatectomy and
radiation therapy (10). Although both of
these approaches are associated with a
good chance of a cure, they are also asso-
ciated with a substantial risk of morbid-
ity, including incontinence, rectal toxic-
ity, and erectile dysfunction (11). Owing
to these conflicting factors, there have
been increased efforts to develop focal
minimally invasive treatment modalities
that can be used to target cancerous tis-
sue while reducing morbidity and treat-
ment duration (12).
Effective image guidance of these min-
imally invasive therapies requires (a) excel-
lent visualization of the prostate and the
surrounding anatomy so that cancerous
tissue can be treated while nearby neural
and vascular structures are avoided and
(b) visualization of the therapeutic agent
itself for direct confirmation that the de-
sired abnormal tissue has been treated. On
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the basis of these conditions, magnetic res-
onance (MR) imaging is the best modality
for image guidance because it yields excel-
lent soft-tissue contrast, has multiplanar
capabilities, and has the potential to yield
spectral and biologic information (13). MR
imaging has been shown to enable far bet-
ter visualization of the prostate and sur-
rounding structures than either US or com-
puted tomography (14). Moreover, with
MR imaging it is possible to visualize in-
jected liquid agents (15,16), solid im-
planted therapeutic seeds (eg, brachyther-
apy seeds) (14,17), and thermal therapy (by
means of both direct temperature monitor-
ing and imaging of tissue damage) (18,19).
We emphasize that the ability to visualize
the therapeutic agent is very enabling in
that it allows direct positive confirmation
of treatment delivery.
The purpose of our study was to dem-
onstrate the use of a transrectal system
that enables precise guidance and moni-
toring of prostate interventions with a
1.5-T MR imaging unit.
Materials and Methods
A mechanically actuated transrectal
needle guide is used to perform MR im-
age–guided needle placement in the
prostate. With a microcoil tracking
method, we are able to quickly (60 msec)
and accurately locate the position and
orientation of the needle guide in the MR
imaging volume. Knowing the position
of the needle enables acquisition of real-
time MR images of an anatomic plane
containing the needle path and determi-
nation of the needle position relative to
previously acquired high-spatial-resolu-
tion images of the prostate.
Device Design
A thin-walled plastic cylindrical sheath
(Delrin plastic; Du Pont, Wilmington, Del)
with a radius of 1.5 cm is inserted into the
rectum to create a stable and stationary
entry point through which the prostate
can be accessed (Fig 1, A). Integral to the
sheath is a 2.5-cm-diameter single-turn coil
for local imaging of the prostate. A window
within the imaging coil in the sheath al-
lows the needle to be advanced from inside
the sheath, through the rectal wall, and
into the body of the prostate.
Next, a cylindrical needle guide (Fig 1,
B), which also is made of Delrin plastic, is
placed in the rectal sheath (Fig 1, C). The
needle guide is coaxial to the rectal
sheath and thus is free to rotate and
translate within the cavity formed by the
sheath without causing deformation of
the surrounding soft tissue. Integral to
the needle guide are three fiducial micro-
coils and a curved channel for the needle
(Fig 1, D). Because the needle channel is
curved, the needle can be inserted along
the axis of the needle guide and emerge
from its lateral wall to allow access to the
prostate through the window in the sta-
tionary rectal sheath.
Next, both the rectal sheath and the nee-
dle guide are affixed to a positioning stage
made of nylon and Delrin plastic (Quality
Transmission Components, New Hyde
Park, NY) (Fig 2, A). This positioning stage
serves to hold the rectal sheath stationary
in the rectum. A linear track (ie, aluminum
rail; 80/20, Columbia City, Ind) and a poly-
amide plastic articulated arm with six
joints allow full mobility of the positioning
stage so that it can be easily docked with
the rectal sheath (Fig 2, B). After the stage is
docked with the sheath, the linear track
and articulated arm are locked down to
prevent subsequent motion.
In addition to holding the rectal
sheath stationary, the positioning stage
contains a screw-drive mechanism that
allows both rotation and translation of
the needle guide. This device converts
the rotation of two concentric control
rods (Epoxy Tubing; TAP Plastics, Dublin,
Calif), both of which extend outside the
magnet bore, into rotation and transla-
tion of the needle guide; this process al-
lows the operator to position the needle
guide while the subject is in the closed
MR magnet bore (Fig 2, C).
The entire device was constructed with
a coaxial design, so the central axis rep-
resents an unobstructed path for inser-
tion of the needle. The depth of needle
insertion is controlled by using a variable
Figure 1. Rectal sheath and needle guide. A, A stationary rectal
sheath with a radius of 1.5 cm forms a stable access route through
which the prostate can be reached. A single-turn rectal imaging coil
with tuning, matching, and decoupling elements is included in the
sheath. A cylindrical needle guide (B) is placed inside the stationary
rectal sheath (C), allowing rotational and translational degrees of
freedom. D, The needle guide includes three tracking microcoils and
a curved needle channel, which allows access to the prostate laterally
through the rectal wall.
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offset stop that is inserted at the back of
the device before the needle is intro-
duced. An 18-gauge coaxial needle (MRI
Devices Daum, Schwerin, Germany) is in-
serted so that the needle tip will emerge
from the side of the needle guide.
Device Tracking, Prostate Targeting,
and Real-Time Imaging
The MR pulse sequences and hardware
were designed to facilitate targeted nee-
dle placement in the prostate within a
1.5-T MR imaging unit (CV/i; GE Medical
Systems, Waukesha, Wis) with four inde-
pendent receiver channels. Three fiducial
microcoils, each connected to a separate
receiver channel, were integrated within
the transrectal needle guide. To deter-
mine the position and orientation of
these coils, we obtained 12 one-dimen-
sional dodecahedrally spaced MR signal
readouts (5.0/2.3 [repetition time msec/
echo time msec], bandwidth of 64 kHz,
1° flip angle, 40-cm field of view, 256
readout points), allowing for coil local-
ization, as described previously (20,21).
MR signal acquisition for coil localization
took approximately 60 milliseconds. Mi-
crocoil localization errors due to gradient
nonlinearity were avoided by using gra-
dient dewarping algorithms (GE Medical
Systems).
Given the positions of the three fidu-
cial microcoils in the MR imaging coor-
dinate system and the location of a given
intraprostatic target (also in the MR im-
aging coordinate system), the remaining
task was to determine (a) the degree of
rotation and translation necessary to po-
sition the needle guide such that the nee-
dle trajectory would be aligned with the
target and (b) the depth of needle inser-
tion necessary to reach the target. These
parameters can be calculated by using a
set of coordinate transformations, with
the assumption that all relationships
among the microcoil positions, device
axis, and needle trajectory are known.
These relationships were established by
using a device-calibration MR image set
on which gadopentetate dimeglumine–
enhanced (Magnevist; Berlex Laborato-
ries, Wayne, NJ) fiducial tubes defined
the device axis and the needle trajectory;
this same calibration image set was used
for all of the studies described herein.
Calibrating the microcoil positions
with the needle trajectory not only al-
lowed for determination of the degree of
rotation and translation necessary to
reach the target site, but it also allowed us
to define the imaging plane that included
both the needle path and the device axis.
Real-time MR images were acquired on the
basis of the position of the fiducial micro-
coils so that the needle could be visualized
as it was being inserted into the prostate.
All experiments were performed by us-
ing the CV/i 1.5-T imaging unit. A fast
gradient-echo (GRE) pulse sequence was
modified to allow alternating acquisition
of the microcoil-tracking MR signal read-
outs (ie, the 12 dodecahedrally spaced
readouts) and real-time fast GRE images.
After the location of each coil was deter-
mined, the position and orientation of
the imaging plane were defined such that
the real-time fast GRE image section con-
tained the path of the needle.
Real-time data were processed and dis-
played on a workstation (Sun Ultra II;
Sun Microsystems, Mountain View,
Calif) that was connected to the imaging
unit with a high-bandwidth data bus
(SBS Technologies, Carlsbad, Calif). With
the described transrectal device, the
tracking sequence is currently performed
in 60 msec; image processing, communi-
cation, and imaging plane localization,
in 150 msec; and image acquisition, in
300–1,300 msec. The entire process
yields frame rates of 0.7–2.0 frames per
second (depending predominantly on
the image acquisition time). One receiver
channel was used for the endorectal im-
aging coil, used to acquire images of the
prostate, whereas the other three receiver
channels were connected to each of the
three fiducial microcoils.
Animal Study Protocol
All animal study protocols were re-
viewed and approved by the Johns Hop-
kins University animal care and use com-
mittee. A technician anesthetized four
mongrel dogs that weighed approxi-
mately 25 kg by means of a bolus injec-
tion of thiopental; anesthesia was main-
tained with 1% isoflurane throughout
the experiment. An intravenous catheter
was placed in the right jugular vein for
fluid administration, and a Foley catheter
was inserted to help stabilize the prostate
and define the position of the prostatic
urethra. The animals were placed in a
prone position on the MR imaging table
with the pelvis slightly elevated (approx-
imately 10 cm), and a 5-inch surface coil
was placed on the anterior surface of the
abdomen at the level of the prostate. The
rectal sheath was inserted into the rec-
tum and docked with the positioning
stage, which was then locked in place. All
Figure 2. Assembled interventional device. A, The stationary rectal sheath and needle guide are
affixed to the positioning stage. With use of a flexible articulated arm and a linear track, the
device can be positioned freely until both the arm and the track are locked into position. The
positioning mechanism converts rotation of the two concentric control rods into rotation and
translation of the needle guide within the stationary rectal sheath. B, The sheath is positioned
inside the rectum and held stationary by the positioning arm and linear track. C, By rotating the
two control rods located outside the bore, the needle guide can be positioned within the rectum.
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experiments were performed by four au-
thors (R.C.S., A.K., G.F., E.A.).
Needle Placement
In the first animal study, the accuracy
of needle placement was tested in vivo.
One canine was positioned in the MR
imaging unit, and then T1-weighted fast
spin-echo (SE) images (700/9.2, band-
width of 31.25 kHz, echo train length
of four, 16-cm field of view, 3-mm sec-
tion thickness, 0.5-mm intersection spac-
ing, 256  256 matrix, four signals ac-
quired, imaging time of 3 minutes) of the
prostate and surrounding anatomy were
acquired. Two receiver channels were
used to acquire these images: one for the
5-inch surface coil and one for the rectal
coil. A target in the body of the prostate
was selected on these images and entered
into the real-time control program. We
then changed to the real-time fast GRE
(5.1/2.3, bandwidth of 64 kHz, 10° flip
angle, 32-cm field of view, 1-cm section
thickness, 256  128 matrix, imaging
time of 0.65 second) imaging and track-
ing sequence.
While performing the real-time fast
GRE MR imaging and tracking sequence,
the operator is able to rotate and trans-
late the needle guide from outside of the
magnet bore by rotating the two coaxial
control rods. On a flat-panel display
screen in the room with the MR imaging
unit, the operator views both the real-
time image section that depicts the tra-
jectory of the needle and the numeric
values that indicate the current degree of
rotation and translation necessary to set
the correct needle trajectory. As the nee-
dle guide is moved closer to the target
area, these numbers move toward zero,
which indicates that no more rotation or
translation is necessary.
Once the needle guide is on the proper
trajectory, the insertion stop is set to the
proper depth (also indicated on the flat-
panel display screen), and the needle is
pushed until its handle is flush with the
stop (Fig 3, A). The insertion of the needle
is visualized on the imaging room display
screen, and once the needle is in place, the
needle tip is at the desired target location.
To confirm the location of the needle
tip, we acquired a second set of T1-
weighted fast SE MR images. These SE MR
images were used to minimize needle sus-
ceptibility artifacts (by minimizing T2*
effects) and therefore maximize the accu-
racy in locating the needle tip. The loca-
tion of the needle tip artifact relative to
the selected target point was compared
by two authors (R.C.S., E.A.). This proto-
col was repeated for four separate needle
insertions.
Intraprostatic Injection
To demonstrate MR image–based
monitoring of injected therapies, intra-
prostatic injections were performed in
two canines. Similar to targets in the nee-
dle placement study, targets for intra-
prostatic injection were selected on
transverse T1-weighted fast SE MR im-
ages, and the needle tip was placed at
these locations by using the real-time fast
GRE MR imaging and tracking sequence.
After the coaxial needle was placed, the
trocar (ie, an inner stylus) was with-
drawn, leaving only the 18-gauge can-
nula (ie, a hollow metal tube) in place.
This process created a conduit through
which injections into the body of the
prostate could be performed (Fig 3, B).
In this experiment, 0.3 mL of a mixture
of 0.4% trypan blue dye (Sigma-Aldrich,
St Louis, Mo) and 30 mmol/L gadopen-
tetate dimeglumine was injected into the
prostate. During the injection, the flow
of the mixture was monitored by using a
high-flip-angle radiofrequency-spoiled fast
GRE MR imaging sequence (6/1.5, 90° flip
angle, bandwidth of 62.5 kHz, 16-cm
field of view, 10-mm section thickness,
256  160 matrix, acquisition time of
0.96 second per image). The location of
the injected solution was determined by
comparing the transverse fast spoiled
GRE MR images (80/2.0, 60° flip angle,
bandwidth of 31.25 kHz, 16-cm field of
view, 3-mm section thickness, 0.5-mm
intersection spacing, 256  256 matrix,
four signals acquired, imaging time of 1
minute 20 seconds) acquired before with
those acquired after the injection. Imme-
diately following the injection proce-
dures and the sacrificing of the animals,
the canine prostates were removed, fixed
in formalin for 24 hours, sliced into
3-mm axial sections, and then photo-
graphed and paired with the correspond-
ing MR image sections by two authors
(R.C.S., E.A.).
Brachytherapy Seed Placement
In a fourth canine, the use of the trans-
rectal device for MR image–guided
brachytherapy seed placement was dem-
onstrated. Targets were selected, and the
trocar and cannula were placed (Fig 3, C),
as previously described herein. Then, to
insert the titanium brachytherapy seeds
(OncoSeed Blanks; Medi-Physics, Arling-
Figure 3. Needle insertion and therapy delivery. A, A variable stop is
used to control the depth of needle insertion. B, After the trocar (ie,
inner stylus) is removed, the cannula remains as a hollow conduit
through which fluid can be injected into the prostate. C, To place
brachytherapy seeds, the trocar and cannula are first advanced to-
gether. D, Then, after the trocar is withdrawn, a brachytherapy seed is
pushed to the end of the cannula with a second trocar. E, With the
trocar held stationary, the cannula is withdrawn, ejecting the seed
into the tissue. The trocar and cannula are then withdrawn together.
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ton Heights, Ill), the trocar was with-
drawn, leaving the hollow cannula in
place in the prostate. We inserted a
brachytherapy seed into the cannula and
then advanced it to the end, but not out,
of the cannula by pushing it with an-
other trocar (Fig 3, D). With the seed at
the end of the cannula, we withdrew the
cannula slightly while holding the trocar
stationary and thus caused the brachy-
therapy seed to be ejected into the pros-
tate tissue. Subsequently, the trocar and
cannula were both withdrawn together
(Fig 3, E). Three seeds were placed by
using this technique. The locations of the
needle and the seeds were confirmed by
using the same T1-weighted fast SE MR
imaging sequence that was used in the
needle placement experiments. The MR
images were evaluated by two authors
(R.C.S., E.A.).
Results
Needle Placement
In the first canine, accurate needle
placement in the body of the prostate
was achieved. The results of this experi-
ment are summarized in Figure 4. In se-
quential order, four targets were selected
on T1-weighted fast SE images (Fig 4, top
row). Having placed the needle by using
the fast GRE real-time MR imaging and
tracking sequence, we performed fast SE
MR imaging again to confirm the place-
ment of the needle by visualizing the
needle void (Fig 4, bottom row). In all
cases, both the end of the needle artifact
and the target were visualized on the
same image section (section thickness, 3
mm). Moreover, the center of the needle
tip void was found within 2 mm (in-
plane) of the selected target. Note also
that there was minimal motion of the
prostate due to insertion of the needle.
To interpret the results of the needle
placement study, it is necessary to exam-
ine the artifact created by the 18-gauge
MR imaging–compatible needle. Figure 5
shows the artifacts created by the needle
and a brachytherapy seed. We aligned the
artifacts by placing the physical objects (ie,
needle and brachytherapy seed) at the in-
terface of gadopentetate dimeglumine–
doped and gadolinium-free gel blocks.
Note that the tip void is a circular bloom
centered at the end of the actual needle, as
has been previously described when the
needle is aligned approximately parallel to
the static magnetic field, or B0, with the tip
toward the positive magnet pole (22). In all
cases, because of the design of the needle
placement system, the needle was approx-
imately parallel to the static magnetic field;
therefore, the artifact position is a good
estimate of the needle tip position.
Because visual confirmation is not pos-
sible in vivo, it was difficult to precisely
quantify the accuracy of in vivo needle
placement. However, in all in vivo exper-
iments, the needle tip was seen on the
same MR imaging section as the target
(section, 3 mm) and in-plane needle po-
sition errors were less than 2 mm.
Intraprostatic Injection
In two canines, the usefulness of this
system for MR image–monitored intra-
prostatic injections was demonstrated.
The box on the sagittal scout MR image
(left image) in Figure 6 indicates the lo-
cation of the time-series MR images ac-
quired during the injection of the gado-
pentetate dimeglumine–trypan blue dye
solution. Note that all of the injected so-
lution remained in the prostate. There-
fore, it was confirmed—during the injec-
Figure 4. Accurate placement of needles in the canine prostate with use of the transrectal needle guide and microcoil tracking. Top: Four target
points in an anesthetized canine were selected on transverse T1-weighted fast SE MR images (700/9.2, bandwidth of 31.25 kHz, echo train length
of four, 16-cm field of view, 3-mm section thickness, 0.5-mm intersection spacing, 256  256 matrix, four signals acquired, imaging time of 3
mimutes). Bottom: Transverse T1-weighted fast SE MR images were obtained again after needle placement. The needle tip artifact and the target were
found on the same image section, with an in-plane separation of less than 2 mm. Also note that there was minimal motion of the prostate upon
needle insertion.
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tion procedure—that the full desired
dose was delivered to the prostatic tissue.
In Figure 7, the distribution of the con-
trast agent–dye solution in the prostate
of one canine, as depicted on MR images,
is compared with the distribution of the
solution seen in the gross tissue slices.
There is good agreement between the ga-
dolinium-enhanced tissue depicted on
the MR images (Fig 7, second column)
and the gross tissue slices stained with
trypan blue dye (Fig 7, third column).
The intraprostatic injection experiment
was repeated in another canine. In this case,
however, the MR images showed the in-
jected contrast agent–dye solution leaking
out of the prostate and into the surround-
ing connective tissue (Fig 8). Therefore, it
was known—during the injection proce-
dure—that the desired dose was not deliv-
ered to the prostate. In Figure 9, the pres-
ence of trypan blue dye in the connective
tissue at the superior margin of the prostate
is confirmed in the gross tissue slices.
Brachytherapy Seed Placement
In the last canine, the application of
this system for brachytherapy seed place-
ment in the prostate was demonstrated.
Figure 10, A shows the selected targets on
coronal MR images of the prostate. Figure
10, B shows MR images obtained in the
same plane after needle placement. Un-
like in the needle placement study, in
this experiment, the tip of the needle
artifact was seen extending beyond the
target point. This is because the brachy-
therapy seeds were placed at the end of
the cannula rather than at the end of the
trocar, which extended 2 mm past the
end of the cannula. Therefore, for proper
seed deposition, the trocar must extend 2
mm past the target point.
Figure 10, C shows the seeds placed in
the prostate after the coaxial needle had
been removed. To interpret these find-
ings, it is helpful to refer to Figure 5,
which shows the artifact pattern created
by the brachytherapy seeds. In Figure 5,
the main signal void is seen at the end of
the 4-mm seed that lies nearest to the
positive pole of the static magnetic field.
This signal void corresponds to the signal
void seen in Figure 10, C. The bodies of
the brachytherapy seeds extend 4 mm
from this void in the inferior direction
(ie, in the direction of the target loca-
tion). The seeds lie within 3 mm of the
selected target location. Also note that
intraprostatic bleeding (ie, the dark
banding radiating toward the edge of the
prostate) resulting from seed placement
can be seen near seeds 2 and 3.
Discussion
Our study results show that needles
can be accurately placed in the body of
the prostate gland while the subject is in
a closed-bore 1.5-T MR imaging unit. Al-
though diagnostic biopsy was not a focus
of the current study, it is an obvious sub-
sequent application. Currently, transrec-
tal US–guided needle biopsy is the refer-
ence standard for the diagnosis of
prostate cancer (23). Although this
method has excellent specificity, it is not
very sensitive. Transrectal US–guided bi-
opsy does not detect the presence of pros-
tate cancer in approximately 20% of
cases (24). MR imaging, in contrast, has
high sensitivity for detection of prostate
tumors (25). MR imaging alone without
concurrent biopsy, however, has low di-
agnostic specificity.
Figure 5. Coronal fast SE MR images (700/9.2, bandwidth of
31.25 kHz, echo train length of four, 8-cm field of view,
1.5-mm section thickness, 256  256 matrix, four signals ac-
quired, imaging time of 3 minutes) obtained in a gel phantom
show artifacts created by A, the prostate needle and B, the
brachytherapy seed. Both objects created a uniform signal void
along their lengths and a circular bloom, centered on the
object tip, at the end facing the positive pole of the static
magnetic field. The labeled arrow (B0) denotes the positive
direction of the static magnetic field. The artifacts were aligned
by placing the physical objects (ie, needle and seed) at the
interface of gadopentetate dimeglumine–doped and gadolin-
ium-free gel blocks.
Figure 6. Intraprostatic injections of a solution consisting of 0.4% trypan blue dye and 30
mmol/L of gadopentetate dimeglumine depicted on fast spoiled GRE MR images. The box on the
sagittal scout MR image (left) indicates the location of the time-series images (6/1.5, 90° flip angle,
bandwidth of 62.5 kHz, 16-cm field of view, 10-mm section thickness, 256  160 matrix,
acquisition time of 0.96 second per image). Note that all of the injected contrast agent–dye
solution remained in the canine prostate. Therefore, it was confirmed that the full desired dose
was delivered to the tissue. t  elapsed time between the beginning of contrast agent adminis-
tration and the image acquisition.
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To take advantage of the high diagnos-
tic sensitivity of MR imaging while main-
taining the specificity of biopsy, the de-
scribed transrectal system may be useful
for performing MR image–guided pros-
tate biopsy. Although it would not be
practical to perform all prostate biopsies
with MR image guidance, the excellent
tissue contrast achieved with MR imag-
ing is very useful for targeted tissue bi-
opsy. In men who have consistently in-
creasing prostate-specific antigen levels
(indicating a high likelihood of cancer)
but repeatedly negative US-guided biopsy
findings, MR image–guided biopsy may
yield a definitive diagnosis. The useful-
ness of MR imaging in this application
area has been demonstrated in a low-
field, open-bore magnet by using a trans-
perineal approach to the prostate (26).
The system described here is well suited
for image-guided biopsy because it uses a
standard transrectal approach to the
prostate and a closed-bore MR unit; thus,
the higher signal-to-noise ratio that is vi-
tal for tumor visualization can be
achieved. Moreover, higher field strength
creates the potential for targeted biopsy
of MR spectroscopically defined prostate
lesions and thus improved diagnostic ac-
curacy (13).
Second, MR image–targeted prostate
biopsy may have the anatomic accuracy
that is necessary for long-term monitor-
ing of prostate lesions. With current US-
guided biopsy procedures, it is very
difficult to repeatedly collect tissue from
the same location in the prostate because
of poor anatomic visualization. Given
the current increase in the early detec-
tion of prostate cancers and the preva-
lence of intermediate-stage prostate tu-
mors, which are associated with an
uncertain prognosis (9), it would be very
useful to be able to repeatedly “sample” a
tumor over a several-year period. This
would allow better clinical decision mak-
ing—for example, definitive prostatec-
tomy or radiation therapy could be de-
layed until it was absolutely necessary or
possibly indefinitely.
With MR imaging, the distribution of
therapeutic agents injected into the pros-
tate can be directly verified. MR imaging
enables visualization of not only the tis-
sue itself but also the therapeutic agent.
It is therefore possible to verify when the
tissue has been treated and, most impor-
tant, when an injection has been unsuc-
cessful—that is, the injected substance
has been delivered into surrounding tis-
sue rather than to the desired target area.
With the advent of local targeted treat-
ments for prostate cancer (12,27), it is
important to confirm that therapy deliv-
ery has been successful. Otherwise, a po-
tentially valuable agent could be labeled
as ineffective because it never reached
the target site.
In the final study of this work, the use-
fulness of MR imaging for guiding
brachytherapy seed placement was dem-
onstrated. Brachytherapy seeds are com-
monly placed by using transrectal US
guidance while the seeds are inserted
through the perineal surface (28). Given
the poor soft-tissue contrast achieved
with US, however, it is common for the
seeds to be misplaced in nearby tissue
(29). In a recent study (30), radiation
Figure 7. Distribution of injected contrast agent–dye solution depicted on transverse fast
spoiled GRE MR images (80/2.0, 60° flip angle, bandwidth of 31.25 kHz, 16-cm field of
view, 3-mm section thickness, 0.5-mm intersection spacing, 256 256 matrix, four signals
acquired, imaging time of 1 minute 20 seconds) and confirmed in gross tissue slices. The
distribution of the gadolinium–blue dye solution as visualized with MR imaging (enhance-
ment seen in postinjection but not preinjection MR images) matches with the distribution
of blue-stained tissue seen in the gross tissue slices.
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seeds were found in the lungs of 36% of
patients after they had undergone US-
guided prostate brachytherapy: Seeds
may be inadvertently placed in the ve-
nous plexus surrounding the prostate,
where they then may travel to the lungs.
MR image–guided seed placement would
be useful in such cases because it yields
good anatomic definition. An MR image–
guided seed placement system would be
suitable for the placement of a few therapy
seeds near a small lesion in the prostate.
Two important aspects of the described
system design need to be emphasized.
First, the stationary rectal sheath is essen-
tial for high-spatial-resolution imaging and
the stability of the prostate. The thin-
walled sheath maintains access to the pros-
tate and thus enables easy rotation and
translation of the needle guide while min-
imizing motion of the surrounding tissue.
Because the rectum is very sensitive to pain
caused by pressure but relatively insensi-
tive to sharp pain, the system can help
minimize patient discomfort during the
positioning of the needle guide. In addi-
tion, the prostate, which is highly deform-
able, stays relatively fixed throughout the
entire procedure. Without the stationary
sheath, motion of the needle guide would
result in substantial deformation of the
prostate, which would complicate the tar-
geting procedure.
Second, we wish to emphasize the im-
portance of using the described transrec-
tal system with a closed-bore 1.5-T MR
imaging unit. The main advantages of
MR imaging are high spatial resolution
and excellent soft-tissue contrast. Al-
though a low-field-strength, open-bore
unit would simplify the design of the
needle guide system, low field strength
marginalizes the usefulness of MR imag-
ing. Therefore, a system that can be used
with a conventional closed-bore magnet
was designed so that high-quality MR im-
aging of the prostate could be main-
tained.
In conclusion, we have described a
transrectal system that allows for image–
based monitoring of prostate therapy in a
closed-bore 1.5-T MR imaging unit. Ap-
plications include MR image–based mon-
itoring of intraprostatic injections and
brachytherapy seed placement. Because
the described transrectal system is used
with closed-bore MR imaging units, it en-
ables one to take advantage of the higher
signal-to-noise ratio achieved with con-
ventional magnet designs. At present, we
are investigating injected therapies such
as those involving the use of alcohol,
chemotherapeutic agents, and genetic
agents.
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Figure 8. MR image–based monitoring enables detection of faulty injections. The box on the
sagittal scout MR image (left) indicates the location of the time-series MR images (6/1.5, 90° flip
angle, bandwidth of62.5 kHz, 16-cm field of view, 10-mm section thickness, 256 160 matrix,
acquisition time of 0.96 second per image). In this canine, the injected contrast agent–dye
solution leaked out of the prostate and into the surrounding connective tissue. Therefore, it was
known—during the procedure—that the desired dose had not been delivered to the prostate. t 
elapsed time between the beginning of contrast agent administration and the image acquisition.
Figure 9. Leakage of injected contrast agent–dye solution into sur-
rounding tissue is confirmed on transverse fast spoiled GRE MR im-
ages (80/2.0, 60° flip angle, bandwidth of 31.25 kHz, 16-cm field of
view, 3-mm section thickness, 0.5-mm intersection spacing, 256 
256 matrix, four signals acquired, imaging time of 1 minute 20
seconds) and in the corresponding gross tissue slices. The distribution
of the gadolinium-based solution, seen as an area of high signal
intensity (arrows) on the MR images, correlates with the distribution
of the solution seen in the stained canine prostate tissue sections.
Although some solution remained in the prostate, some solution also
passed into the connective tissue at the superior left margin of the
posterior region of the prostate.
Volume 228  Number 3 MR Image–guided Prostate Interventions  893
R
a
d
io
lo
gy
References
1. Jemal A, Thomas A, Murray T, Thun M. Cancer
statistics, 2002. CA Cancer J Clin 2002; 52:23–47.
2. Carter HB, Piantadosi S, Isaacs JT. Clinical evi-
dence for and implications of the multistep de-
velopment of prostate cancer. J Urol 1990; 143:
742–746.
3. Slawin KM, Ohori M, Dillioglugil O, Scardino PT.
Screening for prostate cancer: an analysis of the
early experience. CA Cancer J Clin 1995; 45:134–
147.
4. Franks LM. Latent carcinoma of the prostate.
J Pathol Bact 1954; 68:603–616.
5. Dhom G. Epidemiologic aspects of latent and
clinically manifest carcinoma of the prostate. J
Cancer Res Clin Oncol 1983; 106:210–218.
6. Brasso K, Friis S, Juel K, Jorgensen T, Iversen P.
The need for hospital care of patients with clini-
cally localized prostate cancer managed by non-
curative intent: a population based registry
study. J Urol 2000; 163:1150–1154.
7. Adolfsson J, Steineck G, Hedlund PO. Deferred
treatment of clinically localized low-grade pros-
tate cancer: actual 10-year and projected 15-year
follow-up of the Karolinska series. Urology 1997;
50:722–726.
8. Chodak GW, Thisted RA, Gerber GS, et al. Results
of conservative management of clinically local-
ized prostate cancer. N Engl J Med 1994; 330:
242–248.
9. Ohori M, Wheeler TM, Scardino PT. The New
American Joint Committee on Cancer and Inter-
national Union Against Cancer TNM classifica-
tion of prostate cancer: clinicopathologic cor-
relations. Cancer 1994; 74:104–114.
10. Pirtskhalaishvili G, Hrebinko RL, Nelson JB. The
treatment of prostate cancer: an overview of cur-
rent options. Cancer Pract 2001; 9:295–306.
11. Potosky AL, Legler J, Albertsen PC, et al. Health
outcomes after prostatectomy or radiotherapy
for prostate cancer: results from the Prostate
Cancer Outcomes Study. J Natl Cancer Inst 2000;
92:1582–1592.
12. Carroll PR, Presti JC Jr, Small E, Roach M III. Focal
therapy for prostate cancer 1996: maximizing
outcome. Urology 1997; 49:84–94.
13. Koutcher JA, Zakian K, Hricak H. Magnetic reso-
nance spectroscopic studies of the prostate. Mol
Urol 2000; 4:143–152.
14. Yu KK, Hricak H. Imaging prostate cancer. Radiol
Clin North Am 2000; 38:59–85.
15. Lederman RJ, Guttman MA, Peters DC, et al.
Catheter-based endomyocardial injection with
real-time magnetic resonance imaging. Circu-
lation 2002; 105:1282–1284.
16. Yang X, Atalar E, Li D, et al. Magnetic resonance
imaging permits in vivo monitoring of catheter-
based vascular gene delivery. Circulation 2001;
104:1588–1590.
17. D’Amico AV, Cormack R, Tempany CM, et al.
Real-time magnetic resonance image-guided in-
terstitial brachytherapy in the treatment of select
patients with clinically localized prostate cancer.
Int J Radiat Oncol Biol Phys 1998; 42:507–515.
18. Chen JC, Moriarty JA, Derbyshire JA, et al. Pros-
tate cancer: MR imaging and thermometry
during microwave thermal ablation—initial
experience. Radiology 2000; 214:290–297.
19. Graham SJ, Stanisz GJ, Kecojevic A, Bronskill MJ,
Henkelman RM. Analysis of changes in MR
properties of tissues after heat treatment. Magn
Reson Med 1999; 42:1061–1071.
20. Dumoulin CL, Souza SP, Darrow RD. Real-
time position monitoring of invasive devices
using magnetic resonance. Magn Reson Med
1993; 29:411–415.
21. Derbyshire JA, Wright GA, Henkelman RM,
Hinks RS. Dynamic scan-plane tracking using
MR position monitoring. J Magn Reson Imaging
1998; 8:924–932.
22. Liu H, Martin AJ, Truwit CL. Interventional MRI
at high-field (1.5 T): needle artifacts. J Magn Re-
son Imaging 1998; 8:214–219.
23. Presti JC Jr. Prostate cancer: assessment of risk
using digital rectal examination, tumor grade,
prostate-specific antigen, and systematic bi-
opsy. Radiol Clin North Am 2000; 38:49–58.
24. Keetch DW, Catalona WJ, Smith DS. Serial pros-
tatic biopsies in men with persistently elevated
serum prostate specific antigen values. J Urol
1994; 151:1571–1574.
25. Wefer AE, Hricak H, Vigneron DB, et al. Sex-
tant localization of prostate cancer: compari-
son of sextant biopsy, magnetic resonance im-
aging and magnetic resonance spectroscopic
imaging with step section histology. J Urol
2000; 164:400–404.
26. Hata N, Jinzaki M, Kacher D, et al. MR imaging-
guided prostate biopsy with surgical navigation
software: device validation and feasibility. Radi-
ology 2001; 220:263–268.
27. DeWeese TL, van der Poel H, Li S, et al. A phase
I trial of CV706, a replication-competent, PSA
selective oncolytic adenovirus, for the treat-
ment of locally recurrent prostate cancer fol-
lowing radiation therapy. Cancer Res 2001; 61:
7464–7472.
28. Ragde H, Grado GL, Nadir B, Elgamal AA. Mod-
ern prostate brachytherapy. CA Cancer J Clin
2000; 50:380–393.
29. Coakley FV, Hricak H. Radiologic anatomy of the
prostate gland: a clinical approach. Radiol Clin
North Am 2000; 38:15–30.
30. Ankem MK, DeCarvalho VS, Harangozo AM,
et al. Implications of radioactive seed migra-
tion to the lungs after prostate brachytherapy.
Urology 2002; 59:555–559.
Figure 10. MR image guidance enables accurate placement of brachytherapy seeds in a canine
prostate. A, Three target areas in one plane of the prostate were selected on coronal fast SE MR images
(700/9.2, bandwidth of 31.25 kHz, echo train length of four, 16-cm field of view, 3-mm section
thickness, 0.5-mm intersection spacing, 256  256 matrix, four signals acquired, imaging time of 3
minutes). B, The needle was placed at these locations as described previously. Because the brachy-
therapy seeds were placed at the end of the cannula (2 mm back from the end of the trocar tip), the
needle artifact extended beyond the target site by approximately 2 mm. In C, the seeds have been
placed in the prostate. The black bloom artifact at the superior end of the 4-mm brachytherapy seeds
is visible. The seeds extended 4 mm from this artifact in the inferior direction.
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